Robert K. Flamm
#162,303
Most Influential Person Now
Robert K. Flamm's AcademicInfluence.com Rankings
Robert K. Flammbiology Degrees
Biology
#12938
World Rank
#16446
Historical Rank
Microbiology
#787
World Rank
#864
Historical Rank

Download Badge
Biology
Why Is Robert K. Flamm Influential?
(Suggest an Edit or Addition)Robert K. Flamm's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori (1996) (473)
- Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae (1989) (202)
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). (2014) (199)
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. (2014) (196)
- Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. (1997) (194)
- Emergence of macrolide resistance during treatment of pneumococcal pneumonia. (2002) (183)
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) (2013) (171)
- A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori (1997) (169)
- Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. (1999) (162)
- Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995 (2002) (154)
- Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). (2014) (135)
- Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae (2017) (129)
- Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002 (2004) (127)
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). (2014) (124)
- Novel mechanism of macrolide resistance in Streptococcus pneumoniae. (1996) (119)
- Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (2008) (116)
- Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. (1996) (113)
- Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015 (2016) (113)
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012 (2013) (112)
- Characterization and Prevalence of MefA, MefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates (2004) (111)
- Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. (2001) (106)
- Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). (2013) (103)
- Hydrolysis and Inhibition Profiles of β-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem (2009) (103)
- In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone (2003) (103)
- Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. (2011) (96)
- Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. (2000) (94)
- Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 (2012) (94)
- Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). (2013) (93)
- Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae (2016) (93)
- Studies of the Novel Ketolide ABT-773: Transport, Binding to Ribosomes, and Inhibition of Protein Synthesis inStreptococcus pneumoniae (2000) (84)
- Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States (2017) (82)
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. (2017) (81)
- Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016 (2017) (81)
- Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). (2014) (78)
- Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. (2012) (78)
- Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae (1994) (76)
- Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). (2014) (75)
- Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). (2014) (74)
- Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014) (2016) (74)
- Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci (2002) (74)
- In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. (2018) (74)
- Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. (2018) (72)
- In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms (2004) (71)
- WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &bgr;-lactamases (2017) (71)
- Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. (2015) (71)
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013 (2015) (69)
- Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015 (2017) (68)
- In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 (2017) (68)
- Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. (2012) (68)
- Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program (2012) (64)
- Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). (2013) (64)
- Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. (1996) (63)
- In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (2017) (62)
- Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (2018) (62)
- Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010 (2014) (61)
- Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. (2002) (61)
- In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes (2018) (61)
- An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. (2013) (61)
- Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). (2015) (61)
- Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). (2013) (61)
- Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). (2014) (61)
- Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes (1994) (60)
- Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates (2017) (60)
- Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. (2016) (59)
- Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. (2016) (58)
- WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015 (2017) (58)
- Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015) (2017) (56)
- Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. (1999) (56)
- Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016 (2019) (55)
- Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position. (1999) (54)
- LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). (2012) (53)
- Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms (2018) (53)
- In Vitro Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms (2015) (51)
- Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value (2014) (51)
- Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci (2003) (50)
- Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program (2018) (50)
- Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients (2010) (50)
- In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae (2017) (49)
- Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 (2017) (49)
- In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017 (2019) (48)
- ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries (2018) (47)
- Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). (2014) (45)
- Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011 (2013) (45)
- Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016) (2019) (45)
- Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States (2013) (45)
- Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). (2019) (45)
- Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014). (2016) (44)
- Comparative activity of carbapenem testing: the COMPACT study. (2011) (44)
- Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012) (2014) (44)
- Transport and storage ofHelicobacter pylori from gastric mucosal biopsies and clinical isolates (1995) (43)
- Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. (2013) (43)
- Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria (2017) (43)
- Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism (1997) (41)
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015 (2017) (41)
- Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17) (2018) (39)
- A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. (1999) (39)
- Comparative In Vitro Activity of ABT-773, a Novel Antibacterial Ketolide (2001) (39)
- Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011 (2013) (38)
- Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). (2017) (38)
- In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (2016) (38)
- Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016) (2019) (38)
- The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. (2002) (38)
- Fluoroquinolone resistance in Streptococcus pyogenes. (2003) (37)
- Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. (2015) (37)
- ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries (2017) (36)
- Worldwide Experience with the Use of Doripenem against Extended-Spectrum-β-Lactamase-Producing and Ciprofloxacin-Resistant Enterobacteriaceae: Analysis of Six Phase 3 Clinical Studies (2010) (36)
- Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011) (2014) (36)
- Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. (1998) (35)
- Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. (2012) (35)
- Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). (2018) (35)
- Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. (2019) (34)
- Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa (2018) (34)
- In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States (2016) (33)
- Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program (2014) (33)
- Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16 (2018) (32)
- Antibacterial activity of BMS-180680, a new catechol-containing monobactam (1997) (32)
- In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor (1995) (32)
- Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). (2015) (32)
- Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program (2018) (32)
- Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015) (2017) (31)
- Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). (2013) (31)
- 3-Keto-11,12-carbazate derivatives of 6-O-methylerythromycin A synthesis and in vitro activity. (1996) (31)
- In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. (2016) (31)
- Potentiation Effects of Amikacin and Fosfomycin against Selected Amikacin-Nonsusceptible Gram-Negative Respiratory Tract Pathogens (2014) (30)
- Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). (2015) (30)
- In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. (2015) (30)
- Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program (2015) (30)
- Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). (2016) (30)
- Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets (2017) (29)
- Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). (2014) (29)
- Results from the Solithromycin International Surveillance Program (2014) (2016) (29)
- Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014 (2016) (29)
- Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe (2016) (29)
- Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). (2018) (28)
- Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). (2013) (28)
- Surveillance of dalbavancin potency and spectrum in the United States (2012). (2013) (28)
- In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014 (2016) (28)
- Comparison of Broth Microdilution, Agar Dilution, and Etest for Susceptibility Testing of Doripenem against Gram-Negative and Gram-Positive Pathogens (2010) (28)
- Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China (2018) (28)
- Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016 (2018) (27)
- Synthesis and structure-activity relationships of 2-pyridones: II. 8-(Fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents. (1998) (27)
- Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016 (2017) (27)
- Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (2010) (27)
- Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent (2014) (27)
- Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillanc (2018) (27)
- Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains (2015) (26)
- Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States (2015) (26)
- Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections (2001) (26)
- Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). (2018) (26)
- Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. (2019) (26)
- Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations. (2004) (26)
- Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves (2019) (26)
- Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. (2011) (26)
- Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. (2017) (26)
- β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates (2015) (25)
- Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). (2019) (25)
- Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms (2019) (25)
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). (2017) (25)
- Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. (2018) (25)
- Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) (2019) (25)
- In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018 (2019) (24)
- Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). (2015) (24)
- Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. (2002) (24)
- Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014 (2017) (24)
- In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program (2017) (24)
- Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). (2013) (23)
- Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018 (2020) (23)
- Synergistic Activity of Ceftobiprole and Vancomycin in a Rat Model of Infective Endocarditis Caused by Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus (2012) (22)
- Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). (2016) (22)
- Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014 (2016) (22)
- Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. (2008) (22)
- Amikacin-Fosfomycin at a Five-to-Two Ratio: Characterization of Mutation Rates in Microbial Strains Causing Ventilator-Associated Pneumonia and Interactions with Commonly Used Antibiotics (2014) (22)
- Novel 3-deoxy-3-descladinosyl-6-O-methyl erythromycin a analogues. Synthesis and in vitro activity (1997) (21)
- Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from U.S. Medical Centers (2014) (21)
- Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). (2019) (21)
- Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. (2014) (21)
- Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). (2016) (21)
- Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity (2018) (21)
- Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers (2017) (20)
- Efficacy of a New Fluoroquinolone, JNJ-Q2, in Murine Models of Staphylococcus aureus and Streptococcus pneumoniae Skin, Respiratory, and Systemic Infections (2011) (20)
- Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). (2014) (20)
- In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa (2009) (20)
- In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. (2012) (20)
- Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method (2014) (20)
- ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries (2012) (20)
- Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation Program for the United States (2011–2012) (2014) (19)
- In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 (2006) (19)
- Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). (2017) (18)
- Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. (2014) (18)
- Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011) (2014) (18)
- Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. (2018) (18)
- Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. (2018) (18)
- Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. (2012) (18)
- Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. (2020) (18)
- Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America. (2019) (18)
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. (2020) (17)
- PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. (1997) (17)
- Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms (2019) (17)
- Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres (2019) (17)
- Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. (2009) (17)
- Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. (2012) (17)
- Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase (1991) (17)
- Kill kinetics of antimicrobial agents against Helicobacter pylori. (1996) (17)
- Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. (2016) (17)
- Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. (2014) (17)
- Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). (2018) (17)
- Effects of Ceftobiprole and Oxacillin on mecA Expression in Methicillin-Resistant Staphylococcus aureus Clinical Isolates (2009) (17)
- Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016) (2019) (17)
- Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). (2019) (17)
- Comparative Effects of Carbapenems on Bacterial Load and Host Immune Response in a Klebsiella pneumoniae Murine Pneumonia Model (2010) (16)
- In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study. (2010) (16)
- PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin (1997) (16)
- Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. (2012) (16)
- Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015) (2019) (16)
- PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae (2003) (15)
- Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011. (2013) (15)
- Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. (2015) (15)
- Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). (2017) (15)
- Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers (2019) (15)
- In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). (2016) (15)
- Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). (2015) (15)
- In Vitro Activity of A-192411.29, a Novel Antifungal Lipopeptide (2000) (14)
- Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014 (2016) (14)
- Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013 (2015) (14)
- Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226 (2016) (14)
- Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015) (2017) (14)
- Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. (2016) (13)
- Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. (2017) (13)
- Molecular Typing of Helicobacter pylori Isolates from a Multicenter U.S. Clinical Trial by ureC Restriction Fragment Length Polymorphism (1998) (13)
- Activity of fosfomycin when tested against US contemporary bacterial isolates. (2019) (13)
- Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups (2013) (13)
- Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. (2016) (13)
- Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. (2019) (13)
- Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. (2017) (13)
- Ceftaroline Activity Tested against Bacterial Isolates Causing Community-Acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients from United States Hospitals: 2012-2014. (2017) (13)
- Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia (2017) (12)
- Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). (2019) (12)
- In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016) (2017) (12)
- Antimicrobial Activity of First-in-Class Antifungal, Manogepix, and Comparator Agents Testing against Contemporary Invasive Fungal Isolates from an International Surveillance Program (2018-2019): In Vitro Activity of Manogepix against Fungal Isolates. (2021) (12)
- In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. (2016) (11)
- Comparison of emm Typing and Ribotyping with Three Restriction Enzymes To Characterize Clinical Isolates of Streptococcus pyogenes (2005) (11)
- Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018 (2020) (11)
- Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014). (2016) (10)
- Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. (2013) (10)
- Presence of Macrolide Resistance in Respiratory Flora of HIV-Infected Patients Receiving Either Clarithromycin or Azithromycin for Mycobacterium avium Complex Prophylaxis (2001) (10)
- Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program. (2011) (10)
- Mutations in 23S rRNA are associated with clarithromycin resistance in H. pylori (1996) (10)
- Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam (2019) (10)
- Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. (2020) (10)
- Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin (2016) (9)
- Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011). (2014) (9)
- Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). (2017) (9)
- 2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data (2018) (9)
- In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions (2017) (9)
- Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018 (2020) (9)
- Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination. (2017) (9)
- In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates (2020) (9)
- Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH (1997) (9)
- In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States. (2019) (9)
- Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae. (2004) (9)
- Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. (2017) (8)
- A survey of clinical isolates of Enterobacteriaceae using a series of DNA probes for aminoglycoside resistance genes. (1993) (8)
- Antimicrobial Resistance Surveillance and New Drug Development (2019) (8)
- Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa (2018) (8)
- Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin (2015) (7)
- Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia (2019) (7)
- Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. (2017) (7)
- Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates (2018) (7)
- Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae (2015) (7)
- Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). (2016) (7)
- Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016) (2017) (7)
- In Vitro Activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii (2015) (7)
- In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). (2014) (6)
- In Vitro Activity of Delafloxacin and Microbiological Response Against Fluoroquinolone Susceptible and Non-Susceptible S. aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) (2016) (6)
- Surveillance of omadacycline activity tested against clinical isolates from the United States: Report from the SENTRY Antimicrobial Surveillance Program, 2019: Omadacycline 2019 Surveillance - USA. (2021) (6)
- Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole (2016) (6)
- Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017). (2020) (5)
- 1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection (2018) (5)
- Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. (2020) (5)
- Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone (2018) (5)
- Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. (2002) (5)
- Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing (2017) (5)
- Affinity of Ceftobiprole for Penicillin-Binding Protein 2b in Streptococcus pneumoniae Strains with Various Susceptibilities to Penicillin (2010) (5)
- Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010 (2013) (5)
- The new antibacterial class: The ketolides (2000) (5)
- Ceftaroline activity tested against viridans group streptococci from US hospitals. (2016) (5)
- More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. (2013) (5)
- Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients (2020) (4)
- Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide. (2020) (4)
- Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). (2020) (4)
- Regional Analysis of Telavancin and Comparator Antimicrobial Activity against Multidrug-Resistant Staphylococcus aureus Collected in the United States from 2014 through 2016. (2020) (4)
- The application of in vitro surveillance data for antibacterial dose selection (2017) (4)
- Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample. (2013) (4)
- Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections (2019) (4)
- Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program (2017) (4)
- In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program (2017) (4)
- Erratum for Pfaller et al., “In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014” (2018) (4)
- In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015) (2017) (3)
- Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016) (2017) (3)
- In Vitro activity of Fosfomycin (ZTI-01, Fosfomycin for Injection) Against Contemporary Gram-negative and Gram-positive Isolates- a Comparison of Inter-Method Testing (2016) (3)
- In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia (2017) (3)
- Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). (2015) (3)
- Initial Broth Microdilution Quality Control Guidelines for Debio 1452, a FabI Inhibitor Antimicrobial Agent (2015) (3)
- Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). (2017) (3)
- Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018). (2020) (3)
- Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. (2020) (3)
- 3-Keto-11,12-carbazate Derivatives of 6-O-Methylerythromycin A. Synthesis and in vitro Activity (1996) (3)
- Program 2011 United States: LEADER Surveillance Linezolid Surveillance Results for the (2014) (3)
- Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division (2017) (3)
- In Vitro Antibacterial Activity of Meropenem/RPX7009, (a Carbapenem/â-lactamase Inhibitor Combination) against Contemporary Enterobacteriaceae (ENT) Isolated from Intra-abdominal (IAI) and Urinary Tract Infections (UTI) in the United States (USA) (2015) (3)
- Activity of Plazomicin and Comparator Agents Tested Against Gram-negative and -positive Clinical Isolates Collected in USA Hospitals During 2015 (2016) (2)
- The Activity of Tedizolid against Gram-positive Pathogens Isolated From Patients in USA Medical Centers: 2014 Surveillance (2015) (2)
- Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (2017) (2)
- Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results (2016) (2)
- Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016) (2017) (2)
- Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16) (2018) (2)
- 1377. Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms (2018) (2)
- In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). (2020) (2)
- β-lactamase Characterization of Baseline Enterobacteriaceae (ENT) from a Phase 3 Trial of ceftazidime-avibactam (CAZ-AVI) for the Treatment of Infections Caused by CAZ-nonsusceptible (NS) Pathogens (2015) (2)
- Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. (1998) (2)
- 1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018) (2019) (2)
- β-lactamase Characterization of Baseline Pseudomonas aeruginosa (PSA) from Five Ceftazidime-avibactam (CAZ-AVI) Phase 3 Clinical Trials (2017) (2)
- Activity of Pexiganan when Tested Against Contemporary Gram-positive and Gram-negative Bacteria Collected from North America, Europe and Japan (2016) (2)
- Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide (2017) (2)
- Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin (2017) (2)
- 246Frequency of Occurrence and Antimicrobial Susceptibility of Gram-negative Organisms Isolated from Health Care–Associated (HCA) Urinary Tract Infections (UTI) in the United States: Results from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) (2014) (2)
- 1589. Ceftolozane–Tazobactam Activity Against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals (2019) (2)
- The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. (2018) (2)
- Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates (2017) (2)
- 1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA) (2018) (1)
- P2026 Activity of ceftobiprole against Pseudomonas aeruginosa clinical isolates from Europe collected in 2005–2006 (2007) (1)
- Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide (2017) (1)
- Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. (2020) (1)
- 1364. Efficacy of Omadacycline Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials (2018) (1)
- Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) (2016) (1)
- 1523. Antimicrobial Activity of Ceftazidime–Avibactam and Comparator Agents Tested Against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program (2015) (1)
- Telavancin Activity Against Uncommonly Isolated Gram-Positive Pathogens Responsible for Documented Infections in Hospitals Worldwide (2011@2013) When Using A Revised Susceptibility Testing Method (2014) (1)
- 1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type (2020) (1)
- 1584. Minocycline Activity Against Stenotrophomonas maltophilia Isolated From Patients in US Hospitals (2019) (1)
- Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. (2022) (1)
- Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers (2017) (1)
- In vitro activity of omadacycline and comparators against staphylococci, streptococci and enterococci (including resistant organism subsets) from patients in European medical centres during 2016: results from the SENTRY antimicrobial surveillance programme (2017) (1)
- 2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018 (2019) (1)
- 1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States (2018) (1)
- Dalbavancin I n Vitro Activity Obtained Against Gram-positive Clinical Isolates Causing Osteomyelitis in USA Hospitals (2011 - 2015) (2016) (1)
- 1463. Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019) (2020) (1)
- In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program (2017) (1)
- Erratum for Drusano et al., “Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia” (2018) (1)
- 1345. Comparative Activity of Plazomicin and Other Aminoglycosides Against Enterobacteriaceae Isolates From Various Infection Sources From Hospitalized Patients in the United States (2018) (1)
- 2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017) (2018) (1)
- P0093 Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta- lactam resistance mechanisms (2018) (1)
- Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms (2015) (1)
- 470Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013) (2014) (1)
- Activity Of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem Non-Susceptible Pseudomonas Aeruginosa Isolates from USA Hospitals (2016) (1)
- 2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations (2019) (1)
- Multidrug-Resistant Streptococcus pneumoniae (MDRSP) in U.S. Adult Patients: A 2003 Local Perspective (2004) (0)
- Antimicrobial Susceptibility of KPC-producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015) (2016) (0)
- Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016) (2017) (0)
- Prevalence of Main Gram-Positive Pathogens Causing Bloodstream Infections in United States Medical Centers (2010–2015) and Analysis of Oritavancin In Vitro Activity (2016) (0)
- 1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019 (2020) (0)
- Yearly Trends of Antimicrobial Non-susceptibility among Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients in the United States (2009–2015) (2017) (0)
- Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates From Multiple Infection Sources (2016) (0)
- 650: CEFTAZIDIME/AVIBACTAM ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA FROM ICU AND NON-ICU PATIENTS (2016) (0)
- Antimicrobial Activity of High-proportion Cefepime-tazobactam (WCK 4282) When Tested against a Large Worldwide Collection of Gram-negative Organisms (2014) (2017) (0)
- Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs. non-ICU Isolates Collected in US Medical Centers (2017) (0)
- 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) (2019) (0)
- 1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers (2018) (0)
- Comparative Evaluation of the Antimicrobial Susceptibility Patterns of Community- and Hospital-Acquired Methicillin-Resistant S. aureus (MRSA) from USA Hospitals by Site of Infection: Results from the Ceftaroline Surveillance Program AWARE (2012-2014) (2015) (0)
- Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (cid:1) (2008) (0)
- Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013) (2016) (0)
- Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016) (2017) (0)
- 1444. Trends in Antimicrobial Non-susceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States During 2009–2017 (2018) (0)
- 601: CEFTOLOZANE-TAZOBACTAM ACTIVITY VERSUS RESISTANT PSEUDOMONAS AERUGINOSA FROM PNEUMONIA IN THE U.S. (2020) (0)
- 1485. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Contemporary (2015–2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers (2018) (0)
- Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from US Hospitals Stratified by Site of Infection: Results From the INFORM Surveillance Program, 2013–2015 (2016) (0)
- P68 Ceftazidime–avibactam activity tested against Gram-negative bacterial pathogens in the Asia-Pacific region and South Africa (2010) (2013) (0)
- 1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States (2019) (0)
- In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). (2019) (0)
- 1004. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated From Patients Hospitalized With Bloodstream Infections in United States Medical Centers (2015–2017) (2018) (0)
- Activity of Omadacycline When Tested Against Gram-Positive Bacteria Isolated From Patients in the United States During 2015 as Part of a Global Surveillance Program. (2016) (0)
- 247Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013) (2014) (0)
- Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (cid:1) and Chemo-therapy, (2010) (0)
- 116: CEFTAZIDIME-AVIBACTAM TESTED AGAINST GRAMNEGATIVE BACTERIA FROM INTENSIVE CARE UNIT (ICU) PATIENTS (2014) (0)
- Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016) (2017) (0)
- In vitro activity of Iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012-2018. (2021) (0)
- Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015 (2016) (0)
- 1620. Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens (2020) (0)
- Arbekacin Tested against Well Characterized Multidrug-Resistant (MDR) Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus (MRSA) (2014) (0)
- 811Antimicrobial activity of ceftaroline tested against respiratory tract infection (RTI) pathogens isolated from USA medical centers in 2013 (2014) (0)
- Activity of Dalbavancin Tested Against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014 - 2015). (2016) (0)
- 471Antimicrobial Activity and Spectrum of Ceftaroline Tested Against Bacterial Isolates Causing Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers (2014) (0)
- 2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates (2018) (0)
- Antimicrobial Susceptibility of Pseudomonas aeruginosa: Results from Four years (2012-2015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States (2017) (0)
- Analysis of Telavancin in vitro Activity Tested Against a USA Collection of Staphylococcus aureus Clinical Isolates Causing Hospital-acquired Pneumonia (2013-2014) (2015) (0)
- 662: FREQUENCY AND ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIA FROM VENTILATOR-ASSOCIATED PNEUMONIA (2019) (0)
- A Review of Doripenem for the Treatment of Serious Bacterial Infections (2010) (0)
- P1671 Antimicrobial activity of Ceftazidime and Piperacillin-Tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infections (2018) (0)
- 665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections (2019) (0)
- P65 Daptomycin activity when tested against uncommonly isolated streptococcal species and three other Gram-positive species groups (2013) (0)
- Contemporary Analysis of Oritavancin in vitro Activity Against Staphylococcus aureus Responsible for Invasive Community- and Hospital-associated Infections among Patients in the USA (2013-2014) (2015) (0)
- 701. Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods (2019) (0)
- Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: Eight Years of US Surveillance (2009–2016) (2017) (0)
- P64 Ceftaroline activity against common bacterial pathogens causing skin and soft tissue infections in the Asia-Pacific region and South Africa (2013) (0)
- 475Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013) (2014) (0)
- Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011) (2012) (0)
- 1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections (2019) (0)
- Ceftazidime-Avibactam Activity when Tested against Gram-Negative Bacteria Isolated from Patients With Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015). (2016) (0)
- Activity of Dalbavancin against Staphylococci and Streptococci Isolated from United States and European Patients with Blood, Respiratory, and Skin and Soft Tissue Infections (2004) (0)
- Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016) (2017) (0)
- Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox® Annual Appraisal of Potency and Spectrum Program for 2016 (2017) (0)
- Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials (2017) (0)
- 1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program (2018) (0)
- 1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017 (2018) (0)
- Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016) (2017) (0)
- Evaluation of the I n Vitro Activity of Ceftaroline Tested Against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015) (2016) (0)
- 1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates (2019) (0)
- Tight Binding ofClarithromycin, Its14-(R)-Hydroxy Metabolite, andErythromycin toHelicobacter pylori Ribosomes (1994) (0)
- Antimicrobial Activity of Ceftaroline and Comparator Agents tested against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers (2008-2014) (2015) (0)
- P67 Activity of ceftaroline tested against recent (2011) respiratory tract infection pathogens from the Asia Pacific region and South Africa (2013) (0)
- Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016) (2017) (0)
- 729Activity of Ceftaroline and Comparator Agents Tested against Staphylococcus aureus from Patients with Bacteremia in United States (USA) Medical Centers (2009-2013) (2014) (0)
- In Vitro Activity of KPI-10 Tested Against a Global Collection of Acinetobacter spp. Including Multi-Drug Resistant (MDR) Strains (2012) (0)
- Antimicrobial activity of ceftobiprole versus other currently marketed cephalosporins and beta-lactams when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015) (2017) (0)
- 696: FREQUENCY OF OCCURRENCE AND ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIA IN ICU PATIENTS WITH PNEUMONIA (2016) (0)
- Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012–2016 as Part of a Global Surveillance Program (2017) (0)
- Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline (2016) (0)
- Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested Against Gram-negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015) (2016) (0)
- Erratum: Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism (Journal of Clinical Microbiology 35:2 (471)) (1998) (0)
- P66 Antimicrobial activity of ceftazidime–avibactam tested against Pseudomonas aeruginosa from China (2009–2010) (2013) (0)
- Analysis of MIC Relationship Between Tedizolid, Linezolid and Vancomycin Tested Against S. aureus and Enterococcal Clinical Isolates from USA and European Hospitals (2014 - 2015) (2016) (0)
- Helicobacterpylori from Gastric Mucosal Biopsies and Clinical Isolates (0)
- 1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections (2019) (0)
- In vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a USA Collection of Community-acquired Methicillin-resistant Staphylococcus aureus (2014 - 2015) (2016) (0)
- Telavancin Activity Against a Global Collection of Staphylococcus aureus Clinical Isolates (2013–2015) (2017) (0)
- P710 Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005–2006 (2007) (0)
- Comparison of fetal bovine serum and colostrum-free bovine serum supplements of virus culture. (1993) (0)
- P1672 Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenge set of Gram-negative pathogens (2018) (0)
- 1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin (2019) (0)
- 410Tracking Linezolid Antimicrobial Activity and Resistance in North America: Results from LEADER 2013 Program (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert K. Flamm?
Robert K. Flamm is affiliated with the following schools: